GB0520068D0 - av peptide ligand - Google Patents

av peptide ligand

Info

Publication number
GB0520068D0
GB0520068D0 GB0520068A GB0520068A GB0520068D0 GB 0520068 D0 GB0520068 D0 GB 0520068D0 GB 0520068 A GB0520068 A GB 0520068A GB 0520068 A GB0520068 A GB 0520068A GB 0520068 D0 GB0520068 D0 GB 0520068D0
Authority
GB
United Kingdom
Prior art keywords
peptide ligand
ligand
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0520068A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Priority to GB0520068A priority Critical patent/GB0520068D0/en
Publication of GB0520068D0 publication Critical patent/GB0520068D0/en
Priority to ES06794625.1T priority patent/ES2638439T3/es
Priority to CA2624618A priority patent/CA2624618C/en
Priority to US12/088,998 priority patent/US8383593B2/en
Priority to JP2008534069A priority patent/JP5449774B2/ja
Priority to PCT/GB2006/003673 priority patent/WO2007039728A2/en
Priority to CA2854550A priority patent/CA2854550C/en
Priority to EP06794625.1A priority patent/EP1957522B1/en
Priority to US13/743,714 priority patent/US8927501B2/en
Priority to US14/567,274 priority patent/US9650416B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GB0520068A 2005-10-03 2005-10-03 av peptide ligand Ceased GB0520068D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GB0520068A GB0520068D0 (en) 2005-10-03 2005-10-03 av peptide ligand
EP06794625.1A EP1957522B1 (en) 2005-10-03 2006-10-03 AVß6 PEPTIDE LIGANDS AND THEIR USES
JP2008534069A JP5449774B2 (ja) 2005-10-03 2006-10-03 αｖβ６ペプチドリガンド及びその活用
CA2624618A CA2624618C (en) 2005-10-03 2006-10-03 Av.beta.6 peptide ligands and their uses
US12/088,998 US8383593B2 (en) 2005-10-03 2006-10-03 αvβ6 peptide ligands and their uses
ES06794625.1T ES2638439T3 (es) 2005-10-03 2006-10-03 Ligandos peptídicos avß6 y sus usos
PCT/GB2006/003673 WO2007039728A2 (en) 2005-10-03 2006-10-03 AVß6 PEPTIDE LIGANDS AND THEIR USES
CA2854550A CA2854550C (en) 2005-10-03 2006-10-03 .alpha.v.beta.6 peptide ligands and their uses
US13/743,714 US8927501B2 (en) 2005-10-03 2013-01-17 αvβ6 peptide ligands and their uses
US14/567,274 US9650416B2 (en) 2005-10-03 2014-12-11 αvβ6 peptide ligands and their uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0520068A GB0520068D0 (en) 2005-10-03 2005-10-03 av peptide ligand

Publications (1)

Publication Number Publication Date
GB0520068D0 true GB0520068D0 (en) 2005-11-09

Family

ID=35395162

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0520068A Ceased GB0520068D0 (en) 2005-10-03 2005-10-03 av peptide ligand

Country Status (7)

Country Link
US (3) US8383593B2 (https=)
EP (1) EP1957522B1 (https=)
JP (1) JP5449774B2 (https=)
CA (2) CA2624618C (https=)
ES (1) ES2638439T3 (https=)
GB (1) GB0520068D0 (https=)
WO (1) WO2007039728A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
TW200815474A (en) 2006-08-03 2008-04-01 Astrazeneca Ab Antibodies alphaVbeta6 and uses thereof
GB0718843D0 (en) 2007-09-26 2007-11-07 Cancer Rec Tech Ltd Materials and methods relating to modifying the binding of antibodies
MX342270B (es) * 2010-02-18 2016-09-21 The Regents Of The Univ Of California * ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8.
WO2013025261A2 (en) * 2011-04-06 2013-02-21 Georgia Tech Research Corporation Fluorogenic peptide probes and assays
WO2013078250A2 (en) * 2011-11-22 2013-05-30 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides that bind alpha-v-beta-6 integrin
US9403877B2 (en) 2012-01-24 2016-08-02 Inter-K Pty Limited Peptide agents for cancer therapy
US9282120B2 (en) * 2013-02-01 2016-03-08 Vidder, Inc. Securing communication over a network using client integrity verification
GB201311031D0 (en) * 2013-06-20 2013-08-07 Queen Mary & Westfield College Method
JP6789823B2 (ja) * 2014-04-15 2020-11-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 両末端ｐｅｇ化インテグリン結合性ペプチドおよびその使用方法
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
EP3468984A4 (en) * 2016-06-13 2020-03-11 The Regents of the University of California ALPHA (V) BETA (6) BINDING PEPTIDES AND METHODS OF USE THEREOF
BR112018076184A2 (pt) * 2016-06-16 2019-03-26 The University Of Liverpool composição sólida, composição farmacêutica ou veterinária na forma injetável, formulação intramuscularmente injetável, formulação subcutaneamente injetável, dispersão aquosa, dispersão oleosa, processos para preparar uma composição sólida, uma dispersão aquosa e uma dispersão oleosa, métodos para tratar e/ou prevenir uma infecção parasítica ou fúngica e para prevenir malária, e, kit para preparação de uma formulação líquida estéril de nanopartículas de atovaquona para injeção.
ES3023938T3 (en) 2016-09-29 2025-06-03 Univ California Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy
SI3535397T1 (sl) * 2016-11-01 2022-04-29 Arrowhead Pharmaceuticals, Inc. Ligandi alfa-V beta-6 integrina in njihove uporabe
GB201706472D0 (en) * 2017-04-24 2017-06-07 Cancer Res Tech Ltd Tumour-targeting peptide variants
JP7445594B2 (ja) 2017-11-01 2024-03-07 アローヘッド ファーマシューティカルズ インコーポレイテッド インテグリンリガンドおよびその使用
GB201802539D0 (en) * 2018-02-16 2018-04-04 Univ College Cardiff Consultants Ltd Modified adenoviruses
EP3846858A4 (en) * 2018-09-07 2022-10-19 The Regents of the University of California Alpha(v)beta(6) integrin-binding peptides and methods of use thereof
AU2020370362A1 (en) * 2019-10-25 2022-06-02 Children's Medical Center Corporation Computational design of alpha(v) beta (6) integrin binding proteins
WO2021094608A1 (en) * 2019-11-15 2021-05-20 Ospedale San Raffaele S.R.L. Chromogranin a-derived peptides and uses thereof
US12486502B2 (en) 2021-04-08 2025-12-02 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
WO2022221144A1 (en) * 2021-04-12 2022-10-20 University Of Washington Engineered peptides for αvβ6 integrin binding and related methods of use and synthesis
CN115010949B (zh) * 2022-07-12 2024-02-13 华熙生物科技股份有限公司 促渗物、护肤品组合物以及化妆品

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8301928D0 (en) 1983-01-24 1983-02-23 Nicholson B H Process for producing polypeptides
JPS60103596A (ja) * 1983-11-11 1985-06-07 Toshiba Corp サンプル・ホ−ルド回路
AUPM411994A0 (en) * 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
EP1140989A1 (de) 1998-12-19 2001-10-10 MERCK PATENT GmbH Inhibitoren des integrins alpha(v) beta(6)
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
DE19933173A1 (de) * 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
JP2003534558A (ja) * 2000-05-26 2003-11-18 グラクソ グループ リミテッド ＬＡＰ（潜在型結合ペプチド）とインテグリンαｖβ３との間の相互作用のモジュレーターを同定する方法及びその医学的使用
US20030031648A1 (en) * 2000-11-28 2003-02-13 Virogene Ltd. Vectors for expressing heterologous peptides at the amino-terminus of potyvirus coat protein, methods for use thereof, plants infected with same and methods of vaccination using same
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand

Also Published As

Publication number Publication date
EP1957522A2 (en) 2008-08-20
ES2638439T3 (es) 2017-10-20
WO2007039728A3 (en) 2007-09-20
US20150125392A1 (en) 2015-05-07
US20090123370A1 (en) 2009-05-14
CA2624618A1 (en) 2007-04-12
US20130149248A1 (en) 2013-06-13
WO2007039728A2 (en) 2007-04-12
CA2854550C (en) 2020-04-14
JP2009509562A (ja) 2009-03-12
CA2854550A1 (en) 2007-04-12
EP1957522B1 (en) 2017-07-12
US9650416B2 (en) 2017-05-16
US8383593B2 (en) 2013-02-26
JP5449774B2 (ja) 2014-03-19
CA2624618C (en) 2016-03-29
US8927501B2 (en) 2015-01-06

Similar Documents

Publication Publication Date Title
GB0520068D0 (en) av peptide ligand
TWI372152B (en) Novel peptide compounds
IL184428A0 (en) Peptides with neuropeptide-2-receptor
GB0524788D0 (en) Polypeptides
GB0508863D0 (en) Peptide
PL1943406T3 (pl) Typowy element budowlany
GB0525251D0 (en) Oligomerisation
IL184271A0 (en) Peptidic compounds
AP2008004512A0 (en) Bacteriocion inducer peptides
IL189265A0 (en) Ferrocene-diphosphine ligands
GB0414998D0 (en) Monodonor ligands
GB0526019D0 (en) Peptides
GB0505949D0 (en) Polypeptides
GB0516527D0 (en) Peptides
GB0516303D0 (en) Peptide
GB0509835D0 (en) Peptide
GB0523953D0 (en) Peptides
GB0512969D0 (en) Peptides
GB0418568D0 (en) Ligands
GB0403014D0 (en) Ligands
GB0402416D0 (en) Ligands
GB0500592D0 (en) Radiolabelled ligands
GB0500283D0 (en) Radiolabelled ligands
GB0507475D0 (en) Peptide nanoparticles
GB0418414D0 (en) Peptide

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)